CDK9-IN-39

• Description:

  CDK9-IN-39 (1-7a-B1) is an orally active cyclin-dependent kinase 9 (CDK9) inhibitor with an IC50 of 6.51 nM. CDK9-IN-39 induces cell apoptosis by inhibiting the phosphorylation of RNA polymerase II at Ser2 and can be used for study of colorectal cancer [1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; CDK

• Related Pathways:

  Apoptosis; Cell Cycle/DNA Damage

• Field of Research:

  Cancer

• Smiles:

  O=C (NC1=CC (C2=CC=C (C=C2OC (C) C) F) =CC=N1) NC3=CC (C (N4CCN (CC4) C) =O) =CC=C3

• Molecular Formula:

  C27H30FN5O3

• Molecular Weight:

  491.56

• References & Citations:

  [1]Xu J, et al. Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In Vivo. J Med Chem. 2025 Jun 12;68 (11) :11586-11605.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported